Huntingtin Protein is a protein that huntingtin is essential for embryonic development and has multiple functions in the adult nervous system[1]:. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.
Huntingtin (HTT) is one of the largest known proteins, with 3,144 amino acids in the canonical isoform. It is characterized by several structural features[1]:
¶ Domain Architecture
- N-terminal domain (1-90 aa): Contains the polyglutamine (polyQ) tract (CAG repeat, normally 10-35)
- HEAT repeat domain (90-1,700 aa): ~23 HEAT repeats; mediates protein-protein interactions
- Bridge region (1,700-2,200 aa): Flexible linker with multiple proline-rich motifs
- C-terminal domain (2,200-3,144 aa): Contains additional HEAT repeats and regulatory sequences
The HEAT repeats form alpha-helical solenoids that mediate interactions with numerous partner proteins. The polyQ tract length determines pathogenicity—expansion beyond ~36 repeats causes Huntington's disease[1].
- Phosphorylation: At Ser-16, Ser-421, Thr-47 (neuroprotective)
- Acetylation: At Lys-44, Lys-555 (affects aggregation and clearance)
- Sumoylation: Multiple sites
- Palmitoylation: At Cys-214 (membrane association)
- Proteolytic cleavage: By caspases, calpains generating toxic N-terminal fragments
Huntingtin is essential for embryonic development and has multiple functions in the adult nervous system[1]:
- Axonal transport: Associates with dynein/dynactin and kinesin for vesicle movement
- Synaptic vesicle function: Regulates neurotransmitter release
- Endocytic pathway: Involved in receptor trafficking
- Transcriptional co-activator: Interacts with p53, NF-κB, and other transcription factors
- Chromatin remodeling: Associates with histone acetyltransferases (CBP, p300)
- BDNF transcription: Positively regulates BDNF expression
- Anti-apoptotic function: Sequesters pro-apoptotic proteins
- Mitochondrial function: Supports mitochondrial dynamics and quality
- Autophagy regulation: Involved in selective autophagy
- Early development: Essential for gastrulation
- Neuronal survival: Supports cortical and striatal neuron viability
- Synapse formation: Regulates dendritic spine development
CAG repeat expansion (≥36 repeats) causes autosomal dominant Huntington's disease[1]:
- Toxic gain of function: Mutant HTT forms aggregates in neurons[2]
- Loss of normal function: Disrupted protein interactions[2]
- Transcriptional dysregulation: Altered gene expression patterns[2]
- Mitochondrial dysfunction: Energy deficit and oxidative stress[2]
- Axonal transport defects: Impaired vesicle trafficking
- Striatal degeneration: Medium spiny neurons particularly vulnerable
- Cortical atrophy: Progressive loss of cortical volume
- HTT inclusions: Mutant protein aggregates throughout brain
- White matter changes: Demyelination and axonal loss
- Peripheral manifestations: Muscle wasting, metabolic changes
- Cognitive decline: Executive dysfunction, eventually dementia
- Psychiatric symptoms: Depression, anxiety, psychosis
- Alzheimer's disease: HTT may interact with APP and tau
- Parkinson's disease: Altered autophagy in PD linked to HTT
- ALS: HTT inclusions in some ALS cases
- Aggregate formation: Toxic oligomers and inclusions
- Transcriptional dysregulation: Sequestration of transcriptional co-activators
- Mitochondrial dysfunction: Impaired energy metabolism
- Axonal transport disruption: Loss of neurotrophic support
- Synaptic failure: Impaired neurotransmitter release
- Antisense oligonucleotides (ASOs): Multiple clinical trials (e.g., Tominersen, others)
- RNAi and CRISPR: Under development
- Allele-specific targeting: Targeting mutant allele specifically
- Aggregation inhibitors: Small molecules to prevent aggregation
- HTT phosphorylation: Modulating protective phosphorylation sites
- Proteostasis enhancement: Autophagy inducers
- Motor symptoms: Tetrabenazine, VMAT2 inhibitor
- Cognitive dysfunction: Under investigation
- Psychiatric symptoms: Standard treatments
- Neuroprotective strategies: BDNF enhancement, mitochondrial protectants
- Cell replacement therapy: Stem cell approaches under investigation
- Gene therapy: AAV-delivered gene silencing
| Agent |
Target |
Phase |
Status |
Notes |
| Tominersen |
HTT ASO |
I/II |
Discontinued |
Phase 3 halted |
| ASO-HTTRx |
HTT |
I |
Completed |
Dose escalation |
| others |
Various |
Various |
Ongoing |
Multiple approaches |
| Partner |
Interaction Type |
Functional Consequence |
| HAP40 |
Protein binding |
HTT trafficking |
| BDNF |
Transcriptional regulation |
Neurotrophic support |
| CBP/p300 |
Transcription |
Gene expression |
| RAB11 |
Vesicle transport |
Synaptic function |
| p53 |
Apoptosis regulation |
Cell survival |